TI-002 / Trigemina - LARVOL DELTA

TACTI-002: Combination Study With Soluble LAG-3 Fusion Protein Eftilagimod Alpha (IMP321) and Pembrolizumab in Patients With Previously Untreated Unresectable or Metastatic NSCLC, or Recurrent PD-X Refractory NSCLC or With Recurrent or Metastatic HNSCC (clinicaltrials.gov) - P2; N=109; Recruiting; Sponsor: Immutep S.A.; Trial completion date: Jun 2021 ➔ Dec 2021; Trial primary completion date: Jun 2020 ➔ Dec 2020

Clinical • Combination therapy • Trial completion date • Trial primary completion date • Head and Neck Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma of Head and Neck • Thoracic Cancer • PD-L1

"#Immutep Completes Recruitment For Part A Of Phase II #Tacti002 Study $IMMP https://t.co/qdbTjORd7y" (@1stOncology)

"$IMMP IMP321 (The only APC targeting LAG-3 product currently in clinical development) at #SITC2018 : TACTI-mel and TACTI-002 update" (@CaesarBiotech)

Clinical • Oncology

"#Immutep Reports Positive #TACTI002 Data https://t.co/O1cCy8QTyN" (@1stOncology)

"#Immutep to Present #TACTI002 Interim Data at German Cancer Congress $IMMP https://t.co/Jx02R2a9Dj" (@1stOncology)

"#Immutep Expands Part C Of #Tacti002 Due To Positive Data $IMMP https://t.co/PPfVYDMUI0" (@1stOncology)

Immutep Raises A$10 Million Via Private Placement and Underwritten Entitlement Offer (GlobeNewswire, Immutep Limited) - The Company will use the proceeds received from the Private Placement and the Entitlement Offer to finance its LAG-3 related clinical program in immuno-oncology and autoimmune disease. This includes the ongoing clinical development of eftilagimod alpha (“efti” or “IMP321”), via its TACTI-mel, TACTI-002, and INSIGHT clinical studies, development of IMP761 and for general corporate.

Financing

Immutep Presentation at ASCO 2019 (GlobeNewswire, Immutep Limited) - "The two posters related to Immutep’s lead product candidate eftilagimod alpha (“efti” or “IMP321”). The first poster (TPS2667 - #299b) provided an overview of the ongoing Phase II TACTI-002 (Two ACTive Immunotherapies) clinical trial...This multicenter Phase II clinical trial is evaluating the combination of efti with MSD’s KEYTRUDA® (or pembrolizumab, an anti-PD-1 therapy) in up to 109 patients with second line head and neck squamous cell carcinoma or non-small cell lung cancer in first and second line...The second poster related to efti (TPS2651 - #291b) provided an overview of the two additional INSIGHT clinical trial stratas of the prospective investigator-initiated phase I study."

Clinical

TACTI-002: Combination Study With Soluble LAG-3 Fusion Protein Eftilagimod Alpha (IMP321) and Pembrolizumab in Patients With Previously Untreated Unresectable or Metastatic NSCLC, or Recurrent PD-X Refractory NSCLC or With Recurrent or Metastatic HNSCC (clinicaltrials.gov) - P2; N=109; Recruiting; Sponsor: Immutep S.A.; Not yet recruiting ➔ Recruiting

Clinical • Combination therapy • Enrollment open

TACTI-002: Combination Study With Soluble LAG-3 Fusion Protein Eftilagimod Alpha (IMP321) and Pembrolizumab in Patients With Previously Untreated Unresectable or Metastatic NSCLC, or Recurrent PD-X Refractory NSCLC or With Recurrent or Metastatic HNSCC (clinicaltrials.gov) - P2; N=110; Not yet recruiting; Sponsor: Immutep S.A.; Initiation date: Nov 2018 ➔ Feb 2019

Clinical • Combination therapy • Trial initiation date